Commodore Capital LP Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001831942

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallFocusedHealth TiltHigh Turnover how tags are computed

Q3 2023 · 30 positions · Total reported value $855.51M · Top-10 concentration 65.1% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 53.7% · 5 new · 9 cut · 8 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q1 2026 → Q2 2026): +32.0% · vs SPY +17.2% · Prev Value $1.73B — last quarter positions weighted by this quarter price moves · ranking

In its Q3 2023 13F filing, Commodore Capital LP disclosed 30 equity positions with a combined reported value of $855.51M. The filing implies a focused portfolio: its ten largest positions account for 65.1% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2023 were MRUS ($104.41M), VERA ($74.72M), XENE ($63.03M). By sector, the heaviest allocations are Health Care 62.9%, Other 37.1%.

Versus the prior quarter, Commodore Capital LP opened 5 new positions, trimmed 9 and fully exited 8, a turnover rate of 53.7% of positions.

The largest new positions opened in Q3 2023 were MRUS ($104.41M), VERA ($74.72M), XENE ($63.03M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2023)

  • MRUS MERUS N V · $104.41M
  • VERA VERA THERAPEUTICS INC · $74.72M
  • XENE XENON PHARMACEUTICALS INC · $63.03M
  • PCVX VAXCYTE INC · $56.08M
  • COGT COGENT BIOSCIENCES INC · $54.27M
  • RYTM RHYTHM PHARMACEUTICALS INC · $47.57M
  • AMAM AMBRX BIOPHARMA INC · $40.46M
  • ELVN ENLIVEN THERAPEUTICS INC · $39.64M

Fully Exited (vs previous quarter)

No tracked position was fully exited this quarter.

Insider Transactions (Form 4)

Latest Commodore Capital LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Commodore Capital LP, based in New York, NY, United States, files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 33 positions worth $1.68B in total. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Firm Snapshot

  • Headquarters: NEW YORK, NY, United States
  • SEC registration: 801-117168 (status: Approved), registered 2019-08-12
  • Regulatory AUM (Form ADV): $2.37B as of 2026-03-31
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 1 private funds, of which 1 hedge funds
  • Website: commodorecapital.com

Portfolio Structure

  • 33 positions · $1.68B reported value (Q2 2026)
  • Top 10 holdings = 68.2% of reported value
  • Largest position: RLAY (RELAY THERAPEUTICS INC COM) at 13.4%
  • Average position size: $50.88M

Sector Tilt

  • Health Care 94.7%
  • Industrials 3.9%
  • Financials 0.6%
  • (classified holdings cover 99% of value)

Quarterly Activity

  • Q2 2026: 5 new, 6 added, 9 reduced, 8 exited
  • 13 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 62.9%
Other 37.1%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 4.43M $104.41M 12.21%
12.21%
New
2 5.45M $74.72M 8.73%
8.73%
New
3 1.84M $63.03M 7.37%
7.37%
New
4 1.10M $56.08M 6.55%
6.55%
New
5 5.57M $54.27M 6.34%
6.34%
New
6 2.08M $47.57M 5.56%
5.56%
New
7 3.52M $40.46M 4.73%
4.73%
New
8 2.90M $39.64M 4.63%
4.63%
New
9 2.53M $38.44M 4.49%
4.49%
New
10 1.00M $38.39M 4.49%
4.49%
New
11 828.78K $38.10M 4.45%
4.45%
New
12 2.20M $33.75M 3.94%
3.94%
New
13 565.00K $28.58M 3.34%
3.34%
New
14 887.50K $26.19M 3.06%
3.06%
New
15 775.00K $20.91M 2.44%
2.44%
New
16 706.66K $19.45M 2.27%
2.27%
New
17 1.69M $15.48M 1.81%
1.81%
New
18 1.32M $15.17M 1.77%
1.77%
New
19 10.00M $15.00M 1.75%
1.75%
New
20 500.00K $14.87M 1.74%
1.74%
New
21 957.51K $13.90M 1.62%
1.62%
New
22 1.40M $12.77M 1.49%
1.49%
New
23 1.70M $10.86M 1.27%
1.27%
New
24 739.66K $9.08M 1.06%
1.06%
New
25 1.57M $8.25M 0.96%
0.96%
New
26 288.91K $6.41M 0.75%
0.75%
New
27 250.00K $5.33M 0.62%
0.62%
New
28 2.24M $2.85M 0.33%
0.33%
New
29 116.32K $1.42M 0.17%
0.17%
New
30 92.69K $126.05K 0.01%
0.01%
New

FAQ

What did Commodore Capital LP buy in 2023-Q3?

In its 2023-Q3 13F filing, Commodore Capital LP reported 30 equity positions worth $855.51M in aggregate; its largest disclosed positions were MRUS ($104.41M), VERA ($74.72M), XENE ($63.03M).

How large is Commodore Capital LP's portfolio?

Commodore Capital LP reported $855.51M of long equity holdings across 30 positions as of 2023-Q3. Top-10 holdings account for 65.1% of reported value.

What is Commodore Capital LP's investment style?

HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/commodore-capital/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →